Onco Wiki / Maladie

Sarcome des tissus mous (STS)

Vue déterministe de l'entité source de la LJAM. L'autorité clinique demeure avec les ID de la source cités et l'état d'approbation de l ́examinateur.

IDDIS-SOFT-TISSUE-SARCOMA
TypeMaladie
Alias
Sarcome des tissus mous adultesSTSSarcoma des tissus mousSarcome des tissus mousСаркома м'яких тканин
Étatreviewed 2026-05-04 | pending_clinical_signoff
MaladiesAucune déclaration
SourcesAucune déclaration

Informational support. All recommendations must be verified by a qualified oncologist. Engineering checks are not clinical validation or treatment approval.

Source YAML

icd_10C49.9
icd_o_3_morphology8800/3
oncotree_codeST

Capacités

Notes

STS is a heterogeneous family of >50 subtypes. Systemic chemotherapy is moderately effective for most adult STS histologies. Doxorubicin is the most broadly active single agent. Response rates are modest (~10-26%). MDT discussion at a specialized sarcoma center is strongly recommended. Histology matters: GIST → imatinib (separate); bone sarcomas → separate; Ewing → VDC-IE; rhabdomyosarcoma → pediatric protocols.

Utilisé par

Algorithmes

Maladie

Indication

Questionnaires

Signal d’alerte

Protocole thérapeutique

Sources